Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1604008

This article is part of the Research TopicThe Future of Cancer Surveillance ResearchView all 28 articles

Geographical and temporal variations in availability of national price negotiated novel anticancer drugs: a spatial statistical study based on two cross-sectional datasets in China

Provisionally accepted
Ziqi  ZhaoZiqi ZhaoShengwei  ZhangShengwei ZhangTao  ZhengTao ZhengMing  HuMing Hu*
  • West China School of Pharmacy, Sichuan University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

Objective: The National Drug Price Negotiation (NDPN) has significantly reduced the prices and improved the nationwide availability of novel anticancer drugs (NADs) in China. However, geographical disparities in their availability remain concerning. This study aims to assess these spatial variations and temporal changes, and the determinants using geographic information system (GIS) and spatial statistical methods. Methods: Two cross-sectional datasets were used corresponding the implementation date of the 2023 NDPN list (January 1, 2024) and 9 months after (October 1, 2024). Data on drug-providing institutions were extracted from National Healthcare Security Administration (NHSA) platform.Drug availability was measured by the weighted supply number of drug-providing institutions per 1,000 cancer patients, analyzed separately for hospitals and retail pharmacies. Kernel density estimation (KDE) was used to visualize spatial distribution. The Theil index assessed inequality, and Moran's index measured spatial clustering. Multiple linear regression (OLS) and geographically weighted regression (GWR) were employed to examine the influence of economic development and healthcare infrastructure on drug availability.Results: A total of 71 NADs in the 2023 NDPN list were analyzed. By October, drug-providing institutions had become more concentrated in the eastern coastal provinces compared to January.Availability improved in both hospitals and retail pharmacies, with higher levels observed in eastern and central provinces, with lower in the western provinces, especially in the Southwest.Inequality declined and spatial clustering increased for both hospital-based and overall availability across provinces (Theil index, hospital: 0.074-0.062, overall: 0.045-0.044; Moran's I, hospital: 0.315-0.362, overall: 0.452-0.453). Both OLS and GWR models showed a significant and strengthening association between availability (in hospitals and overall) and GDP per capita (e.g. hospital: OLS coef, 0.787-0.833, p<0.001; GWR mean coef[SD], 0.795[0.047]-0.834[0.044]; overall: OLS coef, 0.744-0.794, p<0.01; GWR mean coef[SD], 0.726[0.119]-0.763[0.161]). Retail Formatted: Justified pharmacy-based availability was positively associated with the number of local chain pharmacies (OLS coef, 0.098-0.122, p<0.05; GWR mean coef[SD], 0.084[0.006]-0.107[0.010]). Conclusion: The availability of price-negotiated NADs increasingly concentrated in economically developed and medically advanced eastern provinces, while remaining lower in southwest. Efforts should target economically underdeveloped areas.

Keywords: Drug availability, Health disparities and equity, GIS and spatial statistics, Novel anticancer drugs, Retrospective databases Font: (Default) Times New Roman, (Asian) +Body Asian (DengXian), Font color: Text 1 Formatted: Font: (Default) Times New Roman, Font color: Text 1 Font: (Default) Times New Roman

Received: 02 Apr 2025; Accepted: 15 Jul 2025.

Copyright: © 2025 Zhao, Zhang, Zheng and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ming Hu, West China School of Pharmacy, Sichuan University, Chengdu, 610041, Sichuan Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.